AI Insight
Researchers developed a first-derivative synchronous spectrofluorimetric method for simultaneously quantifying dapagliflozin and sitagliptin, two antidiabetic drugs commonly used in combination therapy. The method successfully detected and measured both compounds in pharmaceutical dosage forms and in spiked human plasma samples without interference between the two drugs. The technique demonstrated good sensitivity, specificity, and accuracy across clinically relevant concentration ranges.
Why it matters
This analytical method provides a simpler, cost-effective alternative to more complex techniques for quality control in pharmaceutical manufacturing and potentially for therapeutic drug monitoring. The ability to measure both drugs simultaneously in plasma could facilitate better dose optimization and patient monitoring in diabetes treatment.
Understand the Science